Ensysce Biosciences Stock Performance
| ENSC Stock | USD 2.13 0.03 1.39% |
On a scale of 0 to 100, Ensysce Biosciences holds a performance score of 4. The firm shows a Beta (market volatility) of 3.89, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ensysce Biosciences will likely underperform. Please check Ensysce Biosciences' maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to make a quick decision on whether Ensysce Biosciences' price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ensysce Biosciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent basic indicators, Ensysce Biosciences exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.39) | Year To Date Return (74.18) | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:15 | Last Split Date 2024-12-06 |
1 | Ensysce Biosciences Stock Doubles In One Trading Session - Heres Why | 04/23/2025 |
2 | Trading Signals - news.stocktradersdaily.com | 05/08/2025 |
3 | Ensysce Biosciences Bolsters Management Team with Regulatory Expert | 05/12/2025 |
4 | Where are the Opportunities in - news.stocktradersdaily.com | 05/19/2025 |
5 | Insider Trading | 05/23/2025 |
6 | Ensysce Biosciences Awarded 5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection | 06/04/2025 |
7 | Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025 ENSC Stock News | 06/11/2025 |
8 | Ensysce Biosciences Advances PF614-MPAR Study with Full Enrollment ENSC Stock News | 06/24/2025 |
9 | Ensysce Biosciences announces exercise of warrants for 2.2M gross proceeds - MSN | 07/09/2025 |
10 | Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - ... | 07/16/2025 |
| Begin Period Cash Flow | 1.1 T |
Ensysce Biosciences Relative Risk vs. Return Landscape
If you would invest 187.00 in Ensysce Biosciences on April 22, 2025 and sell it today you would earn a total of 26.00 from holding Ensysce Biosciences or generate 13.9% return on investment over 90 days. Ensysce Biosciences is currently generating 0.8126% in daily expected returns and assumes 13.3552% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Ensysce, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ensysce Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ensysce Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ensysce Biosciences, and traders can use it to determine the average amount a Ensysce Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0608
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ENSC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.36 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.81 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Ensysce Biosciences is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ensysce Biosciences by adding it to a well-diversified portfolio.
Ensysce Biosciences Fundamentals Growth
Ensysce Stock prices reflect investors' perceptions of the future prospects and financial health of Ensysce Biosciences, and Ensysce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ensysce Stock performance.
| Return On Equity | -2.22 | ||||
| Return On Asset | -0.88 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (1.49) % | ||||
| Current Valuation | 2.25 M | ||||
| Shares Outstanding | 2.37 M | ||||
| Price To Book | 1.66 X | ||||
| Price To Sales | 0.81 X | ||||
| Revenue | 5.21 M | ||||
| Gross Profit | (2.1 M) | ||||
| EBITDA | (6.73 M) | ||||
| Net Income | (7.99 M) | ||||
| Cash And Equivalents | 3.15 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 301.66 K | ||||
| Debt To Equity | 6.91 % | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (7.5 T) | ||||
| Earnings Per Share | 110.31 X | ||||
| Market Capitalization | 5.05 M | ||||
| Total Asset | 5.6 M | ||||
| Retained Earnings | (129.54 T) | ||||
| Working Capital | 3.14 M | ||||
About Ensysce Biosciences Performance
By analyzing Ensysce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Ensysce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ensysce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ensysce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (4.58) | (4.81) | |
| Return On Tangible Assets | (1.43) | (1.50) | |
| Return On Capital Employed | (1.99) | (1.89) | |
| Return On Assets | (1.43) | (1.50) |
Things to note about Ensysce Biosciences performance evaluation
Checking the ongoing alerts about Ensysce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ensysce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ensysce Biosciences is way too risky over 90 days horizon | |
| Ensysce Biosciences appears to be risky and price may revert if volatility continues | |
| Ensysce Biosciences currently holds 301.66 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 5.21 M. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (2.1 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Ensysce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - ... |
- Analyzing Ensysce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ensysce Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ensysce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ensysce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ensysce Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ensysce Biosciences' stock. These opinions can provide insight into Ensysce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |